The Effects of Leukemia Related Gain-of-function Mutant SHP-2 on Murine Angiogenesis in vivo

doi:10.3969/j.issn.1674-5817.2012.04.001

Abstract

Abstract: Objective To study the effect of the activated mutant SHP-2 on murine angiogenesis and its role in tumorigenesis. Methods Heterozygous SHP-2 D61G mutant knock in and wild type C57BL/6 mice were used. The Matrigel containing FGF, VEGF was injected in the local subcutaneous of mouse to induced the angiogenesis. The method of Colorimetric Technique was used to detect the content of Hemoglobin (HB) in the matrigel to represent vascular density. The mouse peripheral blood HB concentration was assayed by the Blood Count Instrument for balance of HB level in matrigel. Then the matrigel was fixed and section was made and done Immunohistochemistry (IHC) for CD31 positive endothelial cell analysis. Finally the Transwell system was used to detect the migrating ability of mouse embryonic fibroblasts (MEFs). Result The HB level was higher in matrigel from SHP-2 D61G mutant mice than that from WT control mice. CD31 positive cells were increased dramatically in matrigel from SHP-2 mutant mouse than that from WT control group(P<0.01). The migration of SHP-2 D61G mutant MEFs were much more than WT MEFs (P<0.01). Conclusion Leukemia related mutant SHP-2 may promote mouse angiogenesis and the promotion effect may be related with the enhanced migrated ability of SHP-2 mutant cell.

Key words: SHP-2, Angiogenesis, Mouse, Gain-of function mutation

CLC Number:

Q95-33

YANG Jin-lian, LU Yan-min, YANG Fan, ZHENG Hong, QU Cheng-kui, WANG Si-ying. The Effects of Leukemia Related Gain-of-function Mutant SHP-2 on Murine Angiogenesis in vivo[J]. Laboratory Animal and Comparative Medicine, 2012, 32(4): 259-264.

References

[1] Tartaglia M, Niemeyer CM, Fragale A, et al.Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia[J]. Nature Genetics,2003, 34(2):148-150.
[2] Bentires-Alj M, Paez JG, David FS, et al.Activating mutations of the noonan syndrome-associated SHP-2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia[J]. Cancer Res,2004, 64(24):8816-8820.
[3] Loh ML, Reynolds MG, Vattikuti S, et al.PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the children's cancer group[J]. Leukemia, 2004,18(11):1831-1834.
[4] Zheng H, Shawn Alter, Qu CK.SHP-2 tyrosine phosphatase in human diseases[J]. Int J Clin Exp Med, 2009, 2(1):17-25.
[5] Marin TM, Keith K, Davies B, et al.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of leopard syndrome-associated PTPN11 mutation[J]. J Clin Invest, 2011, 121(3):1026-1043.
[6] Siying Wang, Wen-Mei Yu, Wanming Zhang, et al.Noonan syndrome/ leukemia- associated gain-of-function mutations in SHP-2 Phosphatase (PTPN11) enhance cell migration and angiogenesis[J]. J Biol Chem, 2009,284(2):913-920.
[7] 张凤英, 余科科, 李菲菲, 等. SHP-2酪氨酸磷酸酶激活突变促进白细胞黏附和迁移的观察[J].安徽医科大学学报,2010, 45(4):487-490.
[8] Yo K., Iwata S., HashizumeY., et al. SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration[J].Biochem Bioph Res Co, 2009, 382(1):210-214.
[9] Zhu JX, Cao G, Williams JT, et al.SHP-2 phosphatase activity is required for PECAM-1-dependent cell motility[J]. Am J Physiol Cell Physiol, 2010, 299(4):854-865.
[10] Qu CK.Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response[J]. Biochim Biophy Acta, 2002,1592(3):297-301.
[11] Neel BG, Gu H, Pao L.The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling[J]. Trends Biochem Sci, 2003, 28(6):284-293.
[12] ZQ Shi, DH Yu, Park M, et al.Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity[J]. Mol Cell Biol, 2000, 20(5):1526-1536.
[13] Barford D, Neel BG.Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2[J]. Structure,1998, 6(1):249-254.
[14] Wang SE, Y Yu, Criswell TL, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators[J]. Oncogene, 2010, 29(23): 3335-3348.
[15] Stefania Mitola, Barbara Brenchio, Marco Piccinini, et al.Type I collagen limits VEGFR-2 signaling by a SHP-2 Protein-Tyrosine phosphatase-dependent mechanism 1[J]. Circ Res, 2006, 98(1):45-54.
[16] Bhattacharya R, Kwon J, Wang E, et al.Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration[J]. J Mol Signal, 2008, 3(8):315-324.
[17] Liangping Yuan,Wen-Mei Yu, Min Xu, et al.SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively[J]. J Biol Chemistry, 2005, 280(52):42701-42706.
[18] Ning Wang, Gerald D. Frank, Zhe Li, et al.Antagonism or synergism: role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling[J]. J Biol Chem, 2006, 281(31):21878-21883.
[19] Tsui FW, Alberto Martin, John Wang, et al.Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase,SHP-1[J].Immunol Res, 2006, 35(1):127-136.
[20] Kapoor GS, Zhan Y, Johnson GR, et al.Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-κB activation through Gab1 in glioblastoma cells[J]. Mol Cell Biol, 2004, 24(2):823-836.
[21] Yao Lua, Yan Xionga,Yingqing Huoa, et al.Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway[J]. PNAS, 2011, 108(7):2957-2962.
[22] Chang Hoon Ha, Anton M.Bennett, and Zheng-Gen Jin. A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor[D]. LMU München, 2007.
[23] Nakashio A, Fujita N, Tsuruo T.Topotecan inhibits VEGF and bFGF-induced vascular endothelial cell migration via down regulation of the PI3K-Akt signaling pathway[J]. Int J Cancer, 2002, 98(1):36-41.
[24] Hanna Karin Mannell, Vallentuna, Schweden,et al.The role of Src-homology 2 domain containin tyrosine phosphatase 2 in growth factor dependent endothelial signalling and angiogenesis[D]. LMU München, 2007.
[25] Yu WM, Daino H, Chen J, et al.Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling[J]. Biol Chem, 2006, 281(9):5426-5434.
[26] Liu X, Qu CK.Protein tyrosine phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis[J]. Signal Transduct, 2011, 29(4):465-473.
[27] Xu D, Wang S, Yu WM, et al.A germline gain-of-function mutation in ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells[J]. Blood, 2010, 116(18):3611-3621.
[28] 张薇, 杨金莲, 胡中倩, 等. SHP-2酪氨酸磷酸酶激活突变导致小鼠髓系异常增殖[J].中国病理生理杂志, 2011, 27(4):682-687.
[29] 张梅, 李菲菲, 郑红, 等. SHP-2酪氨酸磷酸酶在 DNA损伤性放化疗引发的小鼠骨髓毒中的作用[J]. 安徽医科大学学报, 2008, 43(5):480-484.
[30] Allard WJ, Matera J, Miller MC, et al.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J].Clin Cancer Res, 2004, 10(20):6897-6904.